Table 4.
Production yields and analytical purity of nominated sequences and their ability to function as NKCE with humanized cetuximab (ctx) on the GA chain, as indicated by the EC50 for killing of target cells. Evaluation of AC-SINC is included for the one-armed constructs.
| one armed (hu)VHH-SEEDbodies |
VHH x Ctx SEEDbodies |
||||
|---|---|---|---|---|---|
| ID | Yield o.a. [mg/L] | SEC Purity [%] | AC-SINS | SEC Purity [%] | EC50 [nM] |
| FERF.cluster1.4 | 193.2 | 100 | 0.1 | 93.0 | no killing |
| FERF.cluster1.7 | 147.9 | 100 | −0.2 | 95.7 | no killing |
| WT.cluster1.3 | 122.3 | 100 | −0.4 | 96.1 | no killing |
| FERF.cluster2.15 | 183.2 | 100 | 0.0 | 97.6 | 0.05 |
| WT.cluster2.13 | 146.8 | 100 | −0.5 | 97.9 | 4.07 |
| VGLW.cluster2.14 | 98.4 | 100 | −0.3 | 97.1 | no killing |
| FERF.cluster2.10 | 131.3 | 100 | −0.5 | 9.6 | 0.06 |
| FERF.cluster2.11 | 133.4 | 100 | −0.4 | 94.6 | 0.05 |
| WT.cluster5.25 | 193.0 | 100 | −0.4 | 88.8 | 0.03 |
| FERF.cluster5.26 | 221.1 | 97.6 | −0.5 | 9.8 | 4.65 |